Research Institute: Harry Perkins Institute of Medical Research
Amount granted: 1.75 million
Year granted: 2017
The $1.75M ACRF grant will fund three pieces of equipment, including a high throughput next generation DNA sequencer and equipment to isolate single cells from a patient’s tumour.
The equipment will make it possible to analyse thousands of cells from hundreds of tumours and examine billions of genetic sequences to determine the genetic make-up of each tumour and provide new insights into how cancer cells evolve and interact with normal cells.
It will be housed at the world-class single-cell sequencing facility being led by The University of Western Australia’s Professor Forrest at the Harry Perkins Institute of Medical Research in Nedlands.
Single cell analysis of cancer tumours, to see which genes are turned on and off in thousands of cells within a patient’s tumour, is the next wave in cancer research, providing hope to patients that researchers will be able to identify new drugs to combat cancer, better predict a tumour’s response to drugs and develop innovative ways to kill cancer cells.
A consortium of cancer researchers and clinicians across Perth led by Professor Alistair Forrest who heads up the Systems Biology and Genomics Laboratory at the Harry Perkins Institute of Medical Research was recently awarded $3.75M from the Cancer Research Trust to build a comprehensive atlas of the cell types that make up cancer tumours.
What your donations have achieved
Cervical cancer vaccine
We gave initial seed funding to Professor Ian Frazer’s research into the cervical cancer (HPV). Over 150 million doses of vaccine have been delivered worldwide to date.
The pill that melts away cancer
Our long term support of cancer research at WEHI has led to a treatment that melts away certain advanced forms of chronic lymphocytic leukaemia. It has been approved for clinical use in the US, European Union and Australia and is being trialled for other types of cancer.
Personalised cancer diagnosis
In 2015, we awarded $10 million seed funding to an ambitious cancer proteome project that aims to provide each cancer patient a personalised treatment plan within 36 hours. This will improve treatment outcomes and help avoid unnecessary treatments.
Zero childhood cancer
We are one of the founding partners of the initiative that will tackle the most serious cases of infant, childhood and adolescent cancer in Australia. It is a key step towards the program vision of one day helping to cure 100% of children with cancer.